Abivax (ABVX) Beginning Cash Balance (2024 - 2026)

Abivax (ABVX) posted quarterly Beginning Cash Balance of $604.9 million for Q1 2026, up 298.74% year-over-year from $151.7 million in Q1 2025, and up 298.74% quarter-over-quarter from $151.7 million in Q1 2025.

Abivax (ABVX) Beginning Cash Balance (2024 - 2026) Analysis & Trends

Abivax's Beginning Cash Balance history runs 3 years deep, the most recent figure standing at $604.9 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Abivax 9.39 Bn 9.39 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 604.91 Mn
Mar 31, 2026 604.91 Mn
Mar 31, 2025 151.70 Mn
Mar 31, 2025 151.70 Mn
Mar 31, 2024 273.70 Mn
Mar 31, 2024 273.70 Mn